725 studies whose primary subject is depression have been published so far in 2026. Newest first. Back to the depression overview
Current Biology October 19, 2026 John H. Krystal
Ketamine's robust antidepressant effects often appear twenty-four hours after a single dose. A new study now provides evidence suggesting that this timepoint coincides with a quieting of habenula activation and reductions in aversive learning in healthy subjects.
Pharmaceuticals October 19, 2026 Daniel Szawarnoga, Joanna Fojcik, Michał Kamil Górski et al.
Treatment-resistant depression (TRD) remains one of the most clinically challenging forms of depressive disorders. In many patients, reduction in symptom severity does not translate into full functional recovery; therefore, assessment of treatment effectiveness should also include health-related quality of life (HRQoL). Objective: The aim of the study was to compare changes in HRQoL in patients...
Nature Neuroscience October 19, 2026 Patricia Molina, Denys Osypenko, Josep Garnica et al.
Abstract Chronic stress has lasting adverse consequences that can lead, over time, to depressive disorders1‑4 yet identifying the optimal timeframe for effective therapies remains an unmet challenge. Enhanced neuronal activity and disrupted aversion-encoding in lateral habenula (LHb) are important mediators of stress-related behavioral repercussions5‑10, although the precise timing of its...
Therapeutics October 19, 2026 Lukasz Szarpak, Michal Pruc, Dorota Jablonska-Moczulo et al.
Background/Objectives: Treatment-resistant depression (TRD) is heterogeneous and recurrent. Psilocybin administered with structured psychological support can reduce symptoms rapidly. Support protocols differ in content and intensity, and trial design complicates estimates of the specific drug effect and durability. We reviewed efficacy, durability, mechanisms, safety, and clinical delivery in...
Frontiers in Pharmacology October 16, 2026 Qingmei Li, Shuming Liu, Huiling Chen et al.
Objective The molecular mechanisms driving esketamine (ESK) efficacy in the pain-depression dyad (PDD) remain incompletely understood. This study investigated the effects of a sub-anesthetic ESK regimen on cortical expression profiles and exploratory signaling markers within the anterior cingulate cortex (ACC). Methods Male Sprague-Dawley rats were randomized into Sham, PDD, and PDD + ESK...
Frontiers in Psychiatry October 16, 2026 Gilberto Sousa Alves, Humberto M. M. Dos Santos, Samira D Damasceno et al.
Background Esketamine is a promising therapeutic option for treatment-resistant depression (TRD). Intravenous (IV) administration is the most extensively studied parenteral route. However, subcutaneous (SC) administration may offer simpler, more scalable delivery. Multicenter real-world evidence comparing IV and SC routes of administration remains limited. Objective To report clinical outcomes...
Actas Españolas de Psiquiatría October 15, 2026 Huajun Yao, Caihong Peng, Min Wu
Background:To assess whether integrating mindfulness-based stress reduction (MBSR) into refined perioperative nursing is associated with improvements in postoperative sleep disturbances, anxiety, and depression in patients undergoing coronary artery bypass grafting (CABG). Methods: We retrospectively reviewed 146 CABG patients treated at Ruijin Hospital, Shanghai Jiao Tong University School of...
medRxiv October 15, 2026 Chlöé Müh, Pauline Favre, Isabel Karen Lütkenherm et al. preprint
Abstract Negative emotional bias, including reduced processing of positive information and negative interpretation of ambiguous stimuli, is a core feature of depression. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist with rapid antidepressant effects in treatment-resistant depression (TRD), reduces depressive symptoms, but its effects on distinct components of emotional...
Epigenetics October 15, 2026 Arghavan Nepton, Sonya C. Faber, Zachary A. Kaminsky et al.
Ketamine produces rapid antidepressant effects, but the molecular processes associated with their persistence remain poorly defined in humans. We examined longitudinal DNA methylation changes in 10 adults with major depressive disorder undergoing ketamine-assisted psychotherapy using two pre-treatment assessments (T1, T2) and one post-treatment assessment (T3). Participants received three...
Frontiers in Psychology October 14, 2026 Georgi Panov, Presiyana Panova
Both quantum mechanics and cognitive neuroscience challenge the classical view of a passively perceived reality. Instead, they suggest that reality arises through a process of selection and stabilization from a field of possibilities. This article proposes that this “reality stabilization” framework can unify our understanding of psychosis and post-psychotic depression—two conditions that are...
Preprints.org October 14, 2026 Domenico de Berardis, Tommaso Barlattani, Alessandro Carano et al. preprint
Intranasal esketamine has been available for treatment-resistant depression (TRD) since 2019, but the trials that led to its approval answer only some of the questions prescribers face. About 97% of trial participants had failed only one or two antidepressant classes, and patients with bipolar disorder, psychosis, obsessive–compulsive disorder, four personality disorders, moderate-to-severe...
Current Neuropharmacology October 14, 2026 Mareli Vázquez-Barreto, Mariana Ugarte-Rocha, Abraham Flores Vargas et al.
Mental disorders are among the leading causes of non-fatal health loss worldwide and are associated with significant individual, social, and economic burdens. On the other hand, neuropathic pain affects approximately 7-8% of the world's adult population and is a leading reason for medical consultations. A bidirectional relationship between depression and pain has been widely documented....
Research Portal October 13, 2026 Tamsin Ford, Rachel Childs, Rachel Hayes et al.
Adolescents and carers using mindfulness Therapy To END depression (ATTEND): Study Protocol for a parallel randomized controlled superiority trial of Mindfulness for Adolescents and Carers (MAC) for depression among young people aged 15 to 18 years old in the UK with an embedded economic evaluation.
Australasian Psychiatry October 13, 2026 Adam Bayes, Colleen Loo
ObjectiveThe ideas presented in this paper are based on a presentation at a festschrift event marking the retirement of Professor Gordon Parker from UNSW, Sydney. Drawing on Gordon's depressive subtyping approach and his critiques of a unitary view of major depressive disorder and treatment-resistant depression (TRD), we aim to (i) explore differing models of ketamine for TRD - biomedical...
Journal of Affective Disorders October 12, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.
Treatment-resistant depression (TRD) affects 30-60% of individuals with major depressive disorder and carries substantial morbidity and healthcare costs. Intravenous (IV) ketamine (KET) is a rapid-acting antidepressant, but benefits are often transient, prompting augmentation to sustain efficacy or improve tolerability. We conducted a systematic review and meta-analysis of randomized controlled...
Asian Journal of Psychiatry October 12, 2026 Gia Han Le, Sabrina Wong, Simryn Selby et al.
Ketamine is a rapid-acting antidepressant with demonstrated efficacy in major depressive disorder and treatment-resistant depression, yet the mechanisms by which its molecular actions translate into sustained clinical improvement remain incompletely understood. Prevailing models have emphasized N-methyl-D-aspartate receptor antagonism and downstream glutamatergic signaling; however, convergent...
Journal of Molecular Neuroscience October 12, 2026 Meitar Grad, Hadas Volkov, Noam Shomron
Abstract Major depressive disorder (MDD) is a prevalent psychiatric disorder, and is a leading cause of disability worldwide. Current treatments for MDD entail many side effects, and include a lag until the onset of therapeutic effects. The current hypotheses as for the etiology of MDD revolve around the monoamine hypothesis and the plasticity and neurodegeneration hypothesis. According to the...
Research Square October 11, 2026 Kanokwan Wongkhueng, Kedsaraporn Kenbubpha, Palida Phalasak et al. preprint
Abstract Objectives Mindfulness-based cognitive therapy (MBCT) has rarely been tested in non-Western inpatient services or delivered by nurses. This trial evaluated a culturally adapted, nurse-led group MBCT programme for Thai inpatients. Method Ninety-four inpatients with moderate to severe ICD-10 depressive disorder at a Thai psychiatric hospital were randomised 1:1 to MBCT plus routine...
Journal of Affective Disorders Reports October 11, 2026 Elizabeth K. Stierman, Sarah Clifford, Briana E. Kramer et al.
Objective This umbrella review synthesizes evidence about the effectiveness of mindfulness interventions to improve mental health during pregnancy and postpartum. Methods We searched MEDLINE/PubMed, Scopus, Embase.com, PsycInfo, CINAHL, and the Cochrane Database of Systematic Reviews for systematic reviews published between January 1, 2015 and June 26, 2026. We included reviews of randomized...
British Journal of Clinical Psychology October 9, 2026 Russunan Jantarapakdee, Ratchaneekorn Upasen, Penpaktr Uthis et al.
Abstract Objectives This study evaluated the effectiveness of an integrated, application‐supported mindfulness‐based cognitive therapy (MBCT) programme in reducing depressive symptoms among adolescents with non‐suicidal self‐injury (NSSI). Methods An open‐label, two‐arm randomized controlled trial was conducted in two public secondary schools in Thailand. The schools were randomly allocated to...